Company Overview

4SC AG (ISIN DE0005753818) is a drug discovery and development company focused on autoimmune and cancer indications.

4SC-101, a small molecule, is currently in a Phase IIb study in rheumatoid arthritis and a Phase IIa exploratory study in inflammatory bowel disease.

The company’s lead oncology compound, resminostat (4SC-201), a pan histone deacetylase (HDAC) inhibitor, is in Phase II trials in hepatocellular carcinoma and Hodgkin’s lymphoma. 4SC-203, a further oncology compound, is in a Phase I study. 4SC-205 is due to commence a Phase I study shortly.

4SC develops drug candidates until proof-of-concept in order to generate value creating partnerships with the pharmaceutical industry in return for advance and milestone payments as well as royalties.

4SC was founded in 1997, has 93 employees, and is listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.